282 related articles for article (PubMed ID: 35054474)
1. FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?
Lengyel CG; Hussain S; Seeber A; Jamil Nidhamalddin S; Trapani D; Habeeb BS; Elfaham E; Mazher SA; Seid F; Khan SZ; El Bairi K; Odhiambo A; Altuna SC; Petrillo A
Life (Basel); 2022 Jan; 12(1):. PubMed ID: 35054474
[TBL] [Abstract][Full Text] [Related]
2. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration.
Ooki A; Yamaguchi K
Gastric Cancer; 2021 Nov; 24(6):1169-1183. PubMed ID: 34398359
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.
Inokuchi M; Fujimori Y; Otsuki S; Sato Y; Nakagawa M; Kojima K
Gastroenterol Res Pract; 2015; 2015():796380. PubMed ID: 26000013
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor signaling as therapeutic targets in female reproductive system cancers.
Zhu DL; Tuo XM; Rong Y; Zhang K; Guo Y
J Cancer; 2020; 11(24):7264-7275. PubMed ID: 33193890
[TBL] [Abstract][Full Text] [Related]
5. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J
Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351
[TBL] [Abstract][Full Text] [Related]
6. FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.
De Luca A; Esposito Abate R; Rachiglio AM; Maiello MR; Esposito C; Schettino C; Izzo F; Nasti G; Normanno N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962091
[TBL] [Abstract][Full Text] [Related]
7. Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments.
Gordon A; Johnston E; Lau DK; Starling N
Onco Targets Ther; 2022; 15():1183-1196. PubMed ID: 36238135
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges.
Chen L; Zhang Y; Yin L; Cai B; Huang P; Li X; Liang G
J Exp Clin Cancer Res; 2021 Nov; 40(1):345. PubMed ID: 34732230
[TBL] [Abstract][Full Text] [Related]
9. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
[TBL] [Abstract][Full Text] [Related]
10. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
11. Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma.
Balasubramanian B; Yacqub-Usman K; Venkatraman S; Myint KZ; Juengsamarn J; Sarkhampee P; Lertsawatvicha N; Sripa J; Kuakpaetoon T; Suriyonplengsaeng C; Wongprasert K; Grabowska AM; Bates DO; Janvilisri T; Tohtong R
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173994
[TBL] [Abstract][Full Text] [Related]
12. FGFR Signaling as a Target for Lung Cancer Therapy.
Desai A; Adjei AA
J Thorac Oncol; 2016 Jan; 11(1):9-20. PubMed ID: 26762735
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor inhibitors: patent review (2015-2019).
Marseglia G; Lodola A; Mor M; Castelli R
Expert Opin Ther Pat; 2019 Dec; 29(12):965-977. PubMed ID: 31679402
[No Abstract] [Full Text] [Related]
14. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.
Chae YK; Ranganath K; Hammerman PS; Vaklavas C; Mohindra N; Kalyan A; Matsangou M; Costa R; Carneiro B; Villaflor VM; Cristofanilli M; Giles FJ
Oncotarget; 2017 Feb; 8(9):16052-16074. PubMed ID: 28030802
[TBL] [Abstract][Full Text] [Related]
15. Targeting FGFR in bladder cancer: ready for clinical practice?
De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
[No Abstract] [Full Text] [Related]
16. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
King G; Javle M
Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
[TBL] [Abstract][Full Text] [Related]
17. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
Hierro C; Alsina M; Sánchez M; Serra V; Rodon J; Tabernero J
Ann Oncol; 2017 Jun; 28(6):1207-1216. PubMed ID: 28327938
[TBL] [Abstract][Full Text] [Related]
18. FGFR inhibitors in cholangiocarcinoma: what's now and what's next?
Saborowski A; Lehmann U; Vogel A
Ther Adv Med Oncol; 2020; 12():1758835920953293. PubMed ID: 32983265
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.
Biello F; Burrafato G; Rijavec E; Genova C; Barletta G; Truini A; Coco S; Bello MG; Alama A; Boccardo F; Grossi F
Anticancer Agents Med Chem; 2016; 16(9):1142-54. PubMed ID: 26845137
[TBL] [Abstract][Full Text] [Related]
20. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]